These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 17879753

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM, Elkheshen SA, Ghorab MM.
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the complexes of furosemide with 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-7-beta-cyclodextrin.
    Spamer E, Müller DG, Wessels PL, Venter JP.
    Eur J Pharm Sci; 2002 Sep; 16(4-5):247-53. PubMed ID: 12208454
    [Abstract] [Full Text] [Related]

  • 4. Effects of the Preparation Method on the Formation of True Nimodipine SBE-β-CD/HP-β-CD Inclusion Complexes and Their Dissolution Rates Enhancement.
    Semcheddine F, Guissi Nel I, Liu X, Wu Z, Wang B.
    AAPS PharmSciTech; 2015 Jun; 16(3):704-15. PubMed ID: 25511809
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.
    Patel SG, Rajput SJ.
    AAPS PharmSciTech; 2009 Jun; 10(2):660-9. PubMed ID: 19459053
    [Abstract] [Full Text] [Related]

  • 6. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
    Sherje AP, Kulkarni V, Murahari M, Nayak UY, Bhat P, Suvarna V, Dravyakar B.
    Mol Pharm; 2017 Apr 03; 14(4):1231-1242. PubMed ID: 28248111
    [Abstract] [Full Text] [Related]

  • 7. Inclusion Complexes of Hydroxy Propyl-β-Cyclodextrin and Paliperidone: Preparation and Characterization.
    Sherje A, Londhe V.
    Curr Drug Discov Technol; 2014 Apr 03; 11(4):271-8. PubMed ID: 25578059
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The physicochemical characteristics and bioavailability of indomethacin from beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxypropyl-beta-cyclodextrin complexes.
    Jambhekar S, Casella R, Maher T.
    Int J Pharm; 2004 Feb 11; 270(1-2):149-66. PubMed ID: 14726131
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
    Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, Hwang SJ.
    Eur J Pharm Biopharm; 2007 Jun 11; 66(3):413-21. PubMed ID: 17240129
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
    Fathy M, Sheha M.
    Pharmazie; 2000 Jul 11; 55(7):513-7. PubMed ID: 10944779
    [Abstract] [Full Text] [Related]

  • 14. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
    Lima BDS, Campos CA, da Silva Santos ACR, Santos VCN, Trindade GDGG, Shanmugam S, Pereira EWM, Marreto RN, Duarte MC, Almeida JRGDS, Quintans JSS, Quintans LJ, Araújo AAS.
    Food Chem Toxicol; 2019 Apr 11; 126():15-24. PubMed ID: 30738132
    [Abstract] [Full Text] [Related]

  • 15. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
    Lin C, Chen F, Ye T, Zhang L, Zhang W, Liu D, Xiong W, Yang X, Pan W.
    Int J Pharm; 2014 Apr 25; 465(1-2):90-6. PubMed ID: 24530388
    [Abstract] [Full Text] [Related]

  • 16. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
    Hara T, Hirayama F, Arima H, Yamaguchi Y, Uekama K.
    Chem Pharm Bull (Tokyo); 2006 Mar 25; 54(3):344-9. PubMed ID: 16508189
    [Abstract] [Full Text] [Related]

  • 17. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
    Srivalli KM, Mishra B.
    AAPS PharmSciTech; 2016 Apr 25; 17(2):272-83. PubMed ID: 26077622
    [Abstract] [Full Text] [Related]

  • 18. Elucidation of the orientation of selected drugs with 2-hydroxylpropyl-β-cyclodextrin using 2D-NMR spectroscopy and molecular modeling.
    Adhikari S, Daftardar S, Fratev F, Rivera M, Sirimulla S, Alexander K, Boddu SHS.
    Int J Pharm; 2018 Jul 10; 545(1-2):357-365. PubMed ID: 29747001
    [Abstract] [Full Text] [Related]

  • 19. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-beta-cyclodextrin.
    Suihko E, Korhonen O, Järvinen T, Ketolainen J, Jarho P, Laine E, Paronen P.
    Int J Pharm; 2001 Mar 14; 215(1-2):137-45. PubMed ID: 11250099
    [Abstract] [Full Text] [Related]

  • 20. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin.
    Choi HG, Kim DD, Jun HW, Yoo BK, Yong CS.
    Drug Dev Ind Pharm; 2003 Nov 14; 29(10):1085-94. PubMed ID: 14677769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.